Table 2.
Outcomes of 18 patients with CMML or BCR-ABL–negative myeloproliferative syndromes and renal involvement
| Malignancy | Hematologic Treatments |
Follow-up (mo) | Outcomes |
||||
|---|---|---|---|---|---|---|---|
| At diagnosis of the kidney disease | After | eGFR at last follow-up | GFR change | Malignancy | Overall | ||
| MP-CMML-1 | HU | Decitabine | 9.5 | 101 | 28 | Acute myeloid leukemia | Death |
| MD-CMML-2 | No | Azacytidine | 92 | 53 | –2 | Stable | Death |
| MD-CMML-1 | No | Steroids, azacytidine | 19 | 15 | –3 | Stable | Alive |
| MP-CMML-0 | No | HU | 21 | 18 | –51 | Mastocytosis | Death |
| MP-CMML-0 | HU | HU, steroids, azacytidine | 10 | 50 | –25 | Stable | Alive |
| MP-CMML-1 | No | Azacytidine | 2 | 29 | –27 | Stable | Alive |
| MP-CMML-1 | HU | HU, steroids | 1 | 19 | –68 | Stable | Death |
| MP-CMML-0 | No | HU, ruxolitinib | 1 | Dialysis | Dialysis | Stable | Alive |
| ET | No | No | 84 | 58 | –38 | Stable | Alive |
| ET | HU | No | 50 | 54 | –1 | Stable | Death |
| ET | HU | Anagrelide | 2 | 28 | –15 | Stable | Alive |
| ET | HU | No | 48 | Dialysis | Dialysis | Stable | Death |
| ET | HU | Ruxolitinib | 17 | 40 | –35 | Myelofibrosis | Death |
| ET | No | HU, steroids | 21 | 46 | –18 | Stable | Alive |
| ET | HU | No | 17 | Dialysis | Dialysis | Myelofibrosis | Death |
| PV | HU | No | 21 | Dialysis | Dialysis | Acute myeloid leukemia | Death |
| PMF | Steroids, HU | No | 11 | 34 | –14 | Stable | Death |
| SMF (PV) | HU, ruxolitinib, pipobroman | Ruxolitinib | 3 | 36 | –2 | Stable | Alive |
CMML, chronic myelomonocytic leukemia; eGFR, estimated glomerular filtration rate; ET, essential thrombocytosis; GFR, glomerular filtration rate; HU, hydroxyurea; MD, myelodysplastic; MP, myeloproliferative; PMF, primary myelofibrosis; PV, polycythemia vera; SMF, secondary myelofibrosis.